在心肌梗塞后不减少喷射分数的β-阻塞剂:Kaplan-Meier重建的个人患者数据的元分析
Ameer Awashra1, Ahmed Emara2, Ahmed Mazen Amin3
1Department of Medicine, An-Najah National University, Nablus, Palestine.
概括
β-阻断剂 (β-阻断剂) 不能改善心肌梗塞 (MI) 后患者的治疗结果. 常规长期使用在这个人群中没有预后优势.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 药理学 药理学 是一个学科.
背景情况:
- 不确定性围绕着长期β-阻断剂 (β-阻断剂) 在心肌梗塞 (心肌梗塞) 后的好处,在当前再注射时代,在左心室喷射分数 (LVEF ≥ 40%) 保存的患者中.
- 以前的试验表明死亡率有好处,但现代治疗可能会改变这些效应.
研究的目的:
- 进行对随机对照试验 (RCT) 的元分析,评估贝塔阻断剂 (β-阻断剂) 与没有贝塔阻断剂的成年人,患有MI和LVEF≥40%.
- 评估β抑制剂对所有原因死亡率,复发性心脏病发作和心力衰竭 (HF) 的影响.
主要方法:
- 在2025年10月之前通过全面的数据库搜索 (PubMed,Scopus,Web of Science,Cochrane CENTRAL) 识别的五个RCT (n = 23,524名患者) 的元分析.
- 从卡普兰-梅尔曲线重建的个人患者数据 (IPD) 用于时间到事件分析.
- 组合风险比率 (RRs) 和危险比率 (HRs) 估计使用随机效应模型,进行试验序列分析 (TSA) 和元回归.
主要成果:
- β-抑制剂 (β-抑制剂) 并没有显著降低复发性急性心肌梗塞 (AMI) (HR:0.89,P=0.1),心力衰竭 (HF) (HR:0.92,P=0.54),或所有原因死亡率 (HR:0.97,P=0.63).
- 二级终点,包括主要不良心血管事件 (MACE),心血管死亡,中风和再血管,没有显著差异 (P > 0.05).
- 试验序列分析 (TSA) 没有跨越显著性边界,而元回归也没有显示出任何显著的效果修饰者;证据确定性被评为低至中等.
结论:
- 在患有MI和保存LVEF的患者中,β-阻断剂 (β-阻断剂) 不会降低死亡率,缺血事件或高血压.
- 在这个患者群体中,常规长期使用β-阻断剂 (β-阻断剂) 不提供预后优势.
- 贝塔阻断剂 (β阻断剂) 治疗应保留给特定的适应症,如减少LVEF,心痛,心律失常或高血压.
相关概念视频
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...